Pseudoaminopterin syndrome

Pseudoaminopterin syndrome (also known as aminopterin syndrome-like sine aminopterin, or aminopterin/methotrexate embryopathy-like syndrome) is an extremely rare congenital disorder that closely resembles the features seen in fetal aminopterin syndrome but occurs without any known prenatal exposure to aminopterin or methotrexate. The condition primarily affects craniofacial development, the skeletal system, and the skin. Key clinical features include craniosynostosis (premature fusion of skull bones), distinctive facial features such as a broad nasal bridge, hypertelorism (widely spaced eyes), micrognathia (small jaw), and cleft palate. Limb abnormalities may also be present, including short limbs and brachydactyly (short fingers). The ICD-10 classification under Q82.0 reflects associated skin findings, which can include sparse hair and nail anomalies. The syndrome was first described in the medical literature in the 1990s, and only a small number of cases have been reported worldwide. Growth retardation and intellectual disability of variable severity may also be observed in affected individuals. Because of the rarity of the condition, there is no specific targeted therapy. Management is supportive and multidisciplinary, typically involving craniofacial surgery for craniosynostosis, orthopedic care for skeletal anomalies, speech therapy, and developmental support as needed. Genetic counseling is recommended for affected families, although the precise genetic etiology remains incompletely understood in many cases.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Pseudoaminopterin syndrome